Clinical Trial Update: Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 study comparing oral weekly GS-1720 and GS-4182 with Biktarvy in treatment-naive adults with HIV-1 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• GS-1720
• GS-4182

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1-infection | Phase 2, Phase 3 | Status: TERMINATED